Chao Xingjuan sold $973K of CBLL
Chao Xingjuan (President and CEO) sold 39,540 shares of Ceribell, Inc. (CBLL) at $24.61 ($0.97M total) on 2026-09-02 under a Rule 10b5-1 trading plan.
Ceribell, Inc.
No enriched coverage for $CBLL in the last 7 days.
Chao Xingjuan (President and CEO) sold 39,540 shares of Ceribell, Inc. (CBLL) at $24.61 ($0.97M total) on 2026-09-02 under a Rule 10b5-1 trading plan.
Chao Xingjuan (President and CEO) sold 6,068 shares of Ceribell, Inc. (CBLL) at $24.02 ($0.15M total) on 2026-08-21.
Blumberg Scott (Chief Financial Officer) sold 34,502 shares of Ceribell, Inc. (CBLL) at an average of $25.03 ($25.00–$25.03, $0.86M total) across 2 trades over 2026-08-18 to 2026-08-19 under a Rule 10b5-1 trading plan.
Recent CBLL coverage spans insider activity, regulation and financial news.
In the last 30 days, CBLL insiders filed 13 SEC Form 4 transactions — no purchases and 13 sales ($3.3M). The most active reporter was Blumberg Scott, Chief Financial Officer, with 4 filings. 62% of those filings were made under pre-arranged Rule 10b5-1 plans.
Minor dilution and potential negative sentiment from insider sell.
The sale modestly reduces insider ownership but is unlikely to move the stock materially.
Insider sale may signal reduced confidence, potentially pressuring the stock short‑term.
The insider sale may signal confidence concerns but size is modest relative to float.
Regulatory clearance for product enhancements can improve adoption prospects for point-of-care seizure assessment.
alphai scores every news story that mentions CBLL with an AI model for sentiment and relevance, and aggregates insider trades from Ceribell, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Chao Xingjuan (President and CEO) sold 39,540 shares of Ceribell, Inc. (CBLL) at $24.61 ($0.97M total) on 2026-09-02 under a Rule 10b5-1 trading plan.
1 min readChao Xingjuan (President and CEO) sold 6,068 shares of Ceribell, Inc. (CBLL) at $24.02 ($0.15M total) on 2026-08-21.
1 min readBlumberg Scott (Chief Financial Officer) sold 34,502 shares of Ceribell, Inc. (CBLL) at an average of $25.03 ($25.00–$25.03, $0.86M total) across 2 trades over 2026-08-18 to 2026-08-19 under a Rule 10b5-1 trading plan.
1 min readChao Xingjuan (President and CEO) sold 33,614 shares of Ceribell, Inc. (CBLL) at an average of $25.03 ($25.00–$25.03, $0.84M total) across 2 trades over 2026-08-18 to 2026-08-19 under a Rule 10b5-1 trading plan.
1 min readBiopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
7 min readTaylor Joseph Michael sold 13,095 shares of Ceribell, Inc. (CBLL) at $23.40 ($0.31M total) on 2026-08-13.
1 min readCeribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Second Quarter 2026 Financial Results Sunnyvale, Calif. – August 10, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor
6 min readCeribell (CBLL) said the U.S. FDA granted 510(k) clearance for two AI enhancements in its cloud Neurology Portal: epileptiform abnormality detection and artifact reduction. The company says the updates improve EEG signal interpretation and reduce review time. CBLL shares closed Aug. 7, 2026 at $18.81, up 3.07%.
4 min readChao Xingjuan (President and CEO) sold 39,000 shares of Ceribell, Inc. (CBLL) at $18.32 ($0.71M total) on 2026-08-03 under a Rule 10b5-1 trading plan.
1 min readCeriBell Inc. (NASDAQ:CBLL) shares rose about 3% after CMS approved a New Technology Add-on Payment for its Delirium Monitor System. The NTAP allows up to $2,171 per eligible Medicare patient case, starting Oct. 1, 2026, following FDA 510(k) clearance in Dec. 2025.
3 min read